Charles Schwab
ONC

Charles Schwab’s BeOne Medicines Ltd ONC Stock Holding History

Charles Schwab’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,904
Closed -$5.13M – 3414
2020
Q3 		$5.13M Buy
17,904
+1,029
+6% +$242K ﹤0.01% 2046
2020
Q2 		$3.18M Buy
16,875
+185
+1% +$30.1K ﹤0.01% 2248
2020
Q1 		$2.06M Sell
16,690
-37,861
-69% -$5.92M ﹤0.01% 2267
2019
Q4 		$9.04M Buy
54,551
+472
+0.9% +$78.4K ﹤0.01% 1711
2019
Q3 		$6.62M Buy
54,079
+605
+1% +$80.4K ﹤0.01% 1829
2019
Q2 		$6.63M Buy
53,474
+2,844
+6% +$361K ﹤0.01% 1835
2019
Q1 		$6.68M Buy
50,630
+1,994
+4% +$269K ﹤0.01% 1834
2018
Q4 		$6.82M Buy
48,636
+13,310
+38% +$1.77M 0.01% 1714
2018
Q3 		$6.08M Buy
+35,326
New +$5.94M ﹤0.01% 1935

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Charles Schwab's ONC Position: Q4 2020 in Review

Charles Schwab sold out of BeOne Medicines Ltd (ONC) in Q4 2020, closing a stake of 17,904 shares — an estimated $5.13M sold.

Charles Schwab first reported a position in ONC in Q3 2018 and held it in 9 quarters. The position peaked at $9.04M in Q4 2019. 248 funds tracked by Wall St. Rank hold ONC as of Q4 2020.

  • Charles Schwab reported no remaining BeOne Medicines Ltd position as of Q4 2020 after selling out during the quarter.
  • Charles Schwab sold 17,904 BeOne Medicines Ltd shares in Q4 2020, an estimated $5.13M.
  • Charles Schwab first reported a position in BeOne Medicines Ltd in Q3 2018 and held it in 9 quarters.
  • Charles Schwab's BeOne Medicines Ltd position peaked at $9.04M in Q4 2019.
  • 248 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2020.

Based on Charles Schwab's 13F filing for Q4 2020, filed 16 Feb 2021.